Production (Stage)
Celularity Inc.
CELU
$1.76
$0.010.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 49.70% | 145.54% | 312.22% | 273.09% | 193.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.70% | 145.54% | 312.22% | 273.09% | 193.34% |
| Cost of Revenue | -23.58% | 7.80% | 164.71% | -18.12% | 83.13% |
| Gross Profit | 331.04% | 2,841.85% | 367.60% | 575.00% | 323.88% |
| SG&A Expenses | 22.88% | 17.70% | 24.02% | 0.67% | -31.51% |
| Depreciation & Amortization | -32.01% | -32.19% | -16.48% | 0.92% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.24% | 3.67% | -2.16% | -34.02% | -36.00% |
| Operating Income | 12.66% | 29.28% | 48.71% | 74.99% | 65.83% |
| Income Before Tax | -239.09% | 82.85% | 86.47% | 65.61% | -60.91% |
| Income Tax Expenses | -- | -- | -- | -- | -23.08% |
| Earnings from Continuing Operations | -239.24% | 82.85% | 86.47% | 65.61% | -60.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -239.24% | 82.85% | 86.47% | 65.61% | -60.93% |
| EBIT | 12.66% | 29.28% | 48.71% | 74.99% | 65.83% |
| EBITDA | 11.15% | 30.98% | 53.31% | 80.76% | 70.82% |
| EPS Basic | -219.86% | 85.31% | 89.07% | 75.08% | -70.22% |
| Normalized Basic EPS | -204.20% | -23.56% | 78.80% | 74.68% | 136.76% |
| EPS Diluted | -219.86% | 85.31% | 89.07% | 75.08% | -61.26% |
| Normalized Diluted EPS | -204.20% | -23.56% | 78.80% | 74.68% | 146.73% |
| Average Basic Shares Outstanding | 16.16% | 16.70% | 23.75% | 38.00% | 31.21% |
| Average Diluted Shares Outstanding | 16.16% | 16.70% | 23.75% | 38.00% | 3.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |